Inspira's HYLA Blood Sensor Hits 97.35% Accuracy
Ticker: IINNW · Form: 6-K · Filed: Sep 11, 2025 · CIK: 1837493
Sentiment: bullish
Topics: medical-device, fda-submission, accuracy-results
TL;DR
Inspira's HYLA blood sensor is 97.35% accurate, pushing them closer to FDA approval.
AI Summary
On September 11, 2025, Inspira Technologies Oxy B.H.N. Ltd. announced that its HYLA™ Blood Sensor achieved 97.35% accuracy in recent tests. This significant milestone advances the company closer to submitting for FDA clearance, a crucial step for market entry in the United States.
Why It Matters
This high accuracy rate for the HYLA™ Blood Sensor is a critical step towards FDA submission, potentially paving the way for a new medical device that could improve blood monitoring.
Risk Assessment
Risk Level: medium — The company is still awaiting FDA clearance, and the success of the HYLA sensor in the market is not yet guaranteed.
Key Numbers
- 97.35% — HYLA Blood Sensor Accuracy (Indicates high performance in recent tests, moving towards FDA submission.)
Key Players & Entities
- Inspira Technologies Oxy B.H.N. Ltd. (company) — Registrant
- HYLA™ Blood Sensor (product) — Device tested
- 97.35% (dollar_amount) — Accuracy rate
- September 11, 2025 (date) — Announcement date
- FDA (company) — Regulatory body
FAQ
What specific type of blood monitoring does the HYLA™ Blood Sensor aim to improve?
The filing does not specify the exact type of blood monitoring the HYLA™ Blood Sensor aims to improve, but it is presented as a significant advancement in blood sensing technology.
When does Inspira Technologies plan to submit for FDA clearance?
The filing states that the 97.35% accuracy results advance the company 'toward FDA submission for clearance,' implying the submission is imminent but not providing a specific date.
What were the previous accuracy results for the HYLA™ Blood Sensor, if any?
The filing only mentions the recent 97.35% accuracy results and does not provide historical data or previous accuracy figures for the HYLA™ Blood Sensor.
Is the 97.35% accuracy rate based on clinical trials or laboratory testing?
The filing refers to 'accuracy results' without specifying whether they are from clinical trials or laboratory testing.
What is the expected timeline for potential FDA clearance after submission?
The filing does not provide any information regarding the expected timeline for FDA clearance after the submission is made.
Filing Stats: 319 words · 1 min read · ~1 pages · Grade level 8.7 · Accepted 2025-09-11 09:30:02
Filing Documents
- ea0256773-6k_inspira.htm (6-K) — 11KB
- ea025677301ex99-1_inspira.htm (EX-99.1) — 12KB
- ex99-1_001.jpg (GRAPHIC) — 7KB
- 0001213900-25-086686.txt ( ) — 33KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Inspira Technologies Oxy B.H.N. Ltd. Date: September 11, 2025 By: /s/ Dagi Ben-Noon Name: Dagi Ben-Noon Title: Chief Executive Officer 2